SLC5A2 and heart failure: When combined with existing guideline-directed medical therapy, sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin has been shown to minimize hospitalization for heart failure or mortality linked with cardiovascular causes in recent randomized controlled trials, including DAPA-HF [82–84].